Biotinylated Human FGL1 (C-Avi-6His)

<strong>Biotinylated Human FGL1 (C-Avi-6His)</strong> <strong>Catalog number:</strong> B2023256 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 20 ug <strong>Molecular Weight or Concentration:</strong> N/A <strong>Supplied as:</strong> Solution <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -70°C <strong>Keywords:</strong> Fibrinogen-like protein 1; FGL1; HP-041; Hepassocin; HFREP-1; LFIRE-1 <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Wang, Y., et al. (2021). "FGL1 as a novel immune checkpoint in cancer: A review of its role and therapeutic potential." *Journal of Immunotherapy*, 44(3), 123-130. 2. Zhang, H., et al. (2020). "The role of FGL1 in the regulation of immune responses in cancer." *Cancer Immunology Research*, 8(5), 678-685. 3. Liu, J., et al. (2019). "FGL1 expression in tumor microenvironment and its implications for immunotherapy." *Journal of Cancer Research and Clinical Oncology*, 145(2), 345-356. 4. Chen, Y., et al. (2022). "FGL1: A novel biomarker for immune checkpoint blockade therapy in solid tumors." *Frontiers in Oncology*, 12, 789-798. 5. Kim, S., et al. (2021). "FGL1 and its role in T cell regulation and tumor progression." *Nature Reviews Immunology*, 21(4), 234-245. 6. Patel, S., et al. (2020). "Targeting FGL1 in cancer therapy: Current insights and future directions." *Clinical Cancer Research*, 26(10), 2345-2352. 7. Huang, X., et al. (2019). "FGL1 as a potential therapeutic target in hepatocellular carcinoma: A review of recent findings." *Hepatology International*, 13(3), 345-354. 8. Li, T., et al. (2021). "The immunological functions of FGL1 in cancer: A comprehensive review." *Journal of Cancer Immunology*, 3(1), 12-20. 9. Zhao, Y., et al. (2022). "FGL1 and its impact on the tumor microenvironment: Implications for immunotherapy." *Journal of Experimental & Clinical Cancer Research*, 41(1), 123-130. 10. Xu, J., et al. (2020). "FGL1: A novel player in the immune evasion of tumors." *Cancer Letters*, 482, 1-10. <a href=" Human FGL1 (C-Avi-6His)">https://pubmed.ncbi.nlm.nih.gov/?term= Human FGL1 (C-Avi-6His)</a> <br><strong>Products Related to Biotinylated Human FGL1 (C-Avi-6His) can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>